Home›Trial›NCT06413433
🔬NCT06413433Phase 3RECRUITING

Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol

Study Summary

ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of binge eating disorder (BED) in adults.

Conditions
Binge-Eating Disorder
Interventions / Drugs
Solriamfetol 150 mgSolriamfetol 300 mgPlacebo
View on ClinicalTrials.gov ↗
Sponsor
AXSM
Axsome Therapeutics
Neuroscience
D42/100
Study Details
Enrollment450 participants
Primary Completion—
Lead SponsorAxsome Therapeutics, Inc.
Data Retrieved2026-04-11 04:06:36.562782+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.